A comparative study of the relative bioavailability of different interferon beta preparations

Neurology

Volumn 54, Issue 11, 2000, Pages 2055-2060

  Deisenhammer, F ^b   Mayringer, I ^c   Harvey, J ^a   Dilitz, E ^c   Gasse, T ^c   Stadlbauer, D ^c   Reindl, M ^c   Berger, T ^c  

^a BAYER CORPORATION   (United States)

^b UNIVERSITY OF INNSBRUCK   (Austria)

^c NONE

Author keywords

Bioavailability; Interferon beta; MS; MxA; Vascular cell adhesion molecule

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; INTERFERON BETA SERINE; VASCULAR CELL ADHESION MOLECULE 1;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0034643877     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.54.11.2055     Document Type: Article

References (19)

1. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1α for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-294.
2. IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-661.
3. PRISMS (Prevention of Relapses and disability by Interferon β-la Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of Interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352:1498-1504.
4. von Wussow P, Jakschies D, Hochkeppel HK, Fibich C, Penner L, Deicher H. The human intracellular Mx-homologous protein is specifically induced by type I interferons. Eur J Immunol 1990;20:2015-2019.
5. Hartung HP, Reiners K, Archelos JJ, et al. Circulating adhesion molecules and tumor necrosis factor receptor in multiple sclerosis: correlation with magnetic resonance imaging. Ann Neurol 1995;38:186-193.
6. Cannela B, Raine CS. The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann Neurol 1995;37:424-435.
7. Calabresi PA, Tranquill LR, Dambrosia JM, et al. Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon β-1b. Ann Neurol 1997;41:669-674.
8. Deisenhammer F, Reindl M, Harvey J, Gasse T, Dilitz E, Berger T. Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies. Neurology 1999;52:1239-1243.
9. Pungor E, Files JG, Gabe JD, et al. A novel bioassay for the determination of neutralizing antibodies to IFN-β1b. J Interferon Cytokine Res 1998;18:1025-1030.
10. Jiang H, Williams GJ, Dhib-Jalbut S. The effect of interferon beta-1b on cytokine-induced adhesion molecule expression. Neurochem Int 1997;30:449-453.
11. Williams GJ, Witt PL. Comparative study of the pharmacodynamic and pharmacologic effects of Betaseron and Avonex. J Interferon Cytokine Res 1998;18:967-975.
12. Chiang J, Gloff CA, Yoshizawa CN, Williams GJ. Pharmacokinetics of recombinant human interferon-betaser in healthy volunteers and ist effect on serum neopterin. Pharmaceutical Res 1993;10:567-572.
13. Rudick RA, Simonian NA, Alam JA, et al. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Neurology 1998;50:1266-1272.
14. The IFNB Multiple Sclerosis Study Group, University of British Columbia MS/MRI Analysis Group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 1996;47:889-894.
15. Khan OA, Dhib-Jalbut SS. Neutralizing antibodies to interferon beta-1a and interferon beta-1b in MS patients are cross-reactive. Neurology 1998;51:1698-1702.
16. Alam J, McAllister A, Scaramucci J, Jones W, Rogge M. Pharmacokinetics and pharmacodynamics of interferon beta-1a in healthy volunteers after intravenous, subcutaneous or intramuscular administration. Clin Drug Invest 1997;14:35-43.
17. Munafo A, Trinchard-Lugan I, Nguyen TX, Buraglio M. Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon beta-1a after intramuscular and subcutaneous administration. Eur J Neurol 1998;2:187-193.
18. Gruber R. Comparison of pharmacokinetic and pharmacodynamic data of interferon-beta 1a preparations following intramuscular and subcutaneous administration. Drug Res 1998; 48:1043-1046.
19. The Once Weekly Interferon for MS Study Group (OWIMS). Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS study. Neurology 1999;53:679-686.